Medicine Recommendations

Prevention of recurrence of ulcerative colitis following surgery

Second line biologic for moderate to severe active ulcerative colitis ONLY where patients have had adalimumab 1st line

Very severe plaque psoriasis (NICE TA134)

NICE TA134 - Infliximab for the treatment of adults with psoriasis

Acute exacerbations of Ulcerative Colitis (NICE TA163)

NICE TA163 - Infliximab for acute exacerbations of ulcerative colitis

 Crohn's disease, 2nd line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's disease

Crohn's disease, 1st line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab (review) and adalimumab for the treatment of Crohn's disease

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329  Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Ankylosing spondylitis (NICE TA383)

NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis

Treatment of chemotherapy induced colitis

Crohn's disease
Ulcerative colitis

Treatment of chronic asthma in adults and children aged 12 years and over (NICE TA138) and in children under the age of 12 years (NICE TA131)

NICE TA131 - Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years

NICE TA138 - Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over

Peripheral vascular disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

Type 1 and type 2 diabetes mellitus

For the treatment of diabetes mellitus type 1 and 2 in adults

Type 2 diabetes

Type 1 diabetes

Treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control, in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not provide adequate glycaemic control

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above

Type 1 and Type 2 diabetes mellitus

For biosimilars see Insulin glargine biosimilar (Abasaglar®)

Type 1 and Type 2 diabetes mellitus